Table 2.
Summary of outcomes by exposure to the intervention, with adjusted and unadjusted intervention effects
| Unexposed arm | Exposed arm | Percentage difference (95% CI for primary outcomes and 99% CI for secondary outcomes) | ||
|---|---|---|---|---|
|
| ||||
| Unadjusteda | Time adjustedb | |||
| Persons (person years) | 2969 (1939.33) | 2926 (1795.48) | ||
|
| ||||
| Treatment initiation, n(%) | ||||
| Antihypertensives or statins | 321 (10.8) | 577 (19.7) | 9.7 (7.9 to 11.4) P<0.001 | 15.5 (3.9 to 27.1) P= 0.009 |
| Antihypertensives | 222 (7.5) | 333 (11.4) | 4.7 (3.4 to 6.1) P<0.001 | 7.7 (−0.1 to 15.5) P= 0.054 |
| Statins | 188 (6.3) | 405 (13.8) | 7.7 (6.2 to 9.2) P<0.001 | 9.5 (3.0 to 16.0) P= 0.004 |
| Antiplatelet agents or over-the-counter aspirin | 235 (7.9) | 263 (9.0) | 2.5 (1.8 to 3.2) P<0.001 | 2.5 (−1.6 to 6.7) P= 0.230 |
|
| ||||
| Measurement of CVD risk factors, n(%) | ||||
| Patients with BP assessed | 825 (27.8) | 1285 (43.9) | 17.2 (14.3 to 20.0) P<0.001 | 28.8 (−3.5 to 59.1) P= 0.022 |
| Patients with lipids assessed | 437 (14.7) | 1046 (35.7) | 21.1 (18.4 to 23.9) P<0.001 | 26.4 (5.3 to 47.5) P= 0.001 |
|
| ||||
| Cardiovascular events, n(%) | ||||
| CVD events | 27 (0.91) | 17 (0.58) | 0.1 (−0.3 to 0.6) P= 0.486 | 0.3 (−1.6 to 2.2) P= 0.685 |
|
| ||||
| Referrals, n(%) | ||||
| Referral to smoking cessation | 12 (0.40) | 30 (1.03) | 0.6 (0.1 to 1.2) P= 0.002 | 3.3 (0.8 to 5.9) P= 0.001 |
| Referral to diet or physical activity advice | 4 (0.13) | 5 (0.17) | 0.0 (−0.2 to 0.3) P= 0.730 | −0.6 (−1.5 to 0.2) P= 0.055 |
a
The unadjusted model is adjusted for clustering.
b
The time-adjusted model is adjusted for the effect of time, clustering, and practice priority.
BP = blood pressure. CVD = cardiovascular disease.